Pipelines: We are building robust and highly differentiated product pipelines through multiple development approaches, with a strong focus on cutting-edge technologies such as radioligand drug conjugates (RDCs)  and AI-powered mRNA platforms, aiming to become a leader in treating cancer as a chronic disease.

Proven Commercial Value: Our first commercialized product, Envafolimab®, the world’s first subcutaneous PD-(L)1 antibody, has achieved over RMB 1.7 billion in cumulative sales within three years of launch.

Exceptional Leadership Team: Our leadership team has global R&D and commercialization expertise, with deep experience in FDA engagement and multinational pharma operations.